Kelun-Biotech Announces Breakthrough Therapy Designation Granted for Sacituzumab Tirumotecan (Sac-TMT) in Combination With Tagitanlimab in China for Certain Types of Non-Small Cell Lung Cancer
This marks the fifth Breakthrough Therapy Designation granted to sac-TMT by the NMPA. Sac-TMT has previously received this designation for:
Locally advanced or metastatic triple-negative breast cancer (TNBC) in July 2022;
EGFR-mutant, locally advanced or metastatic NSCLC after progression on EGFR-TKI therapy in January 2023;
Locally advanced or metastatic hormone-receptor positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer (BC) in patients who have previously received at least two lines of systemic chemotherapy in June 2023；
First-line treatment of unresectable locally advanced, recurrent or metastatic PD-L1 negative TNBC in March 2024.
Results from a Phase 2 OptiTROP-Lung01 study of sac-TMT in combination with tagitanlimab in first-line advanced or metastatic non-squamous NSCLC patients were presented in a poster session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting[1].
Dr. Michael Ge, CEO of Kelun-Biotech said, "This designation by the NMPA highlights the importance of developing novel therapeutic options for diverse NSCLC subtypes. Sac-TMT in combination with tagitanlimab demonstrated clinically meaningful outcomes in key endpoints for patients with non-squamous NSCLC without actionable genomic alterations as a first-line treatment. We are excited about the therapeutic potential of TROP2 ADC- immunotherapy combinations, and we look forward to working with regulatory authorities in China to bring this combination therapy to patients in need as soon as possible."
[1] Abstract #8529: Lung Cancer – Non-Small Cell Metastatic, ASCO Annual Meeting, 2025
About sac-TMT (佳泰莱®)Sac-TMT, a core product of the Company, is a novel human TROP2 ADC in which the Company has proprietary intellectual property rights, targeting advanced solid tumors such as NSCLC, BC, gastric cancer (GC), gynecological tumors, among others. Sac-TMT is developed with a novel linker to conjugate the payload, a belotecan-derivative topoisomerase I inhibitor with a drug-to-antibody-ratio (DAR) of 7.4. Sac-TMT specifically recognizes TROP2 on the surface of tumor cells by recombinant anti-TROP2 humanized monoclonal antibodies, which is then endocytosed by tumor cells and releases KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable, it can enable a bystander effect, or in other words kill adjacent tumor cells.
In May 2022, the Company licensed the exclusive rights to MSD (the tradename of Merck & Co., Inc., Rahway, NJ, USA) to develop, use, manufacture and commercialize sac-TMT in all territories outside of Greater China (includes Mainland China, Hong Kong, Macao, and Taiwan).
To date, two indications for sac-TMT have been approved and marketed in China for the treatment of adult patients with unresectable locally advanced or metastatic TNBC who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting) and EGFR mutation-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-TKI therapy and platinum-based chemotherapy. Sac-TMT became the first domestic ADC with global intellectual property rights to be fully approved for marketing. It is also the world's first TROP2 ADC to be approved for marketing in a lung cancer indication. In addition, two new indication applications for sac-TMT for the treatment of adult patients with EGFR-mutant locally advanced or metastatic NSCLC who progressed after treatment with EGFR-TKI therapy and with unresectable locally advanced, metastatic HR+/HER2- BC who have received prior endocrine therapy and other systemic treatments in the advanced or metastatic setting were accepted by the CDE, and were included in the priority review and approval process. As of today, the Company has initiated 8 registrational clinical studies in China. MSD has initiated 14 ongoing Phase 3 global clinical studies of sac-TMT as a monotherapy or with pembrolizumab2 or other agents for several types of cancer. These studies are sponsored and led by MSD.
About Tagitanlimab (科泰莱®)Tagitanlimab is the first PD-L1 mAb globally to receive authorization for the first-line treatment of NPC. Previously, the NMPA has approved the marketing in China of tagitanlimab used in combination with cisplatin and gemcitabine for the first-line treatment of patients with R/M NPC and monotherapy for the treatment of patients with recurrent or metastatic NPC who have failed after prior 2L+ chemotherapy, respectively.
About Kelun-BiotechKelun-Biotech (6990.HK) is a holding subsidiary of Kelun Pharmaceutical (002422.SZ), which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. The company focuses on major disease areas such as solid tumors, autoimmune, inflammatory, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. The Company is committed to becoming a leading global enterprise in the field of innovative drugs. At present, the Company has more than 30 ongoing key innovative drug projects, of which 3 projects have been approved for marketing, 1 project is in the NDA stage, and more than 10 projects are in the clinical stage. The company has established one of the world's leading proprietary ADC platforms, OptiDC™, and has 1 ADC project approved for marketing, 1 ADC project in NDA stage, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit https://kelun-biotech.com/.
Media: klbio_pr@kelun.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/kelun-biotech-announces-breakthrough-therapy-designation-granted-for-sacituzumab-tirumotecan-sac-tmt-in-combination-with-tagitanlimab-in-china-for-certain-types-of-non-small-cell-lung-cancer-302478438.html
SOURCE Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
14 hours ago
- Associated Press
DermRays Celebrates 13 Years of Skincare Innovation with Exclusive Anniversary Sale and Groundbreaking 1450nm Laser Device for 2026
PLEASANTON, Calif., Aug. 15, 2025 /PRNewswire/ -- DermRays, a pioneer in at-home skincare technology, marks its 13th anniversary with a celebration of its best-selling devices and a sneak peek at its upcoming 1450nm laser skincare tool, slated for launch in early 2026. This milestone underscores the brands commitment to merging cutting-edge science with accessible beauty solutions. Anniversary Spotlight: Award-Winning Skincare Heroes To thank customers for their trust, DermRays is offering limited-time discounts on three transformative devices designed to rejuvenate skin at home: 1. DermRays Revive The first and only at-home laser with ultra-high energy for collagen regeneration. Ideal for reducing fine lines and boosting collagen, its a clinic-grade tool for a fraction of the cost. Revive uses cutting-edge 1064nm laser technology, the same as that employed by leading salon brands. 2. FusionGlow Multi-Functional Microcurrent Toning Device Beyond Microcurrent: 5 Skincare Technologies You Need. Comprehensive Skin Revitalization: Brighten, Hydrate, Rejuvenate. Achieve radiant, firm skin in 14 days with clinically visible results backed by SGS. 3. LED Light Therapy Silicone Mask Your daily skincare companion: blue, red, infrared, and mixed light for every need. Only 15 minutes a day for youthful and radiant skin. 'For 13 years, we've empowered users to take control of their skincare routines with safe, effective technology,' says Dr. Yang Lin, Brand Director at DermRays. 'Our anniversary sale is a tribute to our community-and just the beginning of whats next.' 4. The Future: 1450nm Laser Skincare Device DermRays is set to revolutionize at-home treatments again with its 1450nm laser device (expected Q1 2026). It stimulates natural collagen production to smooth fine lines, restore firmness, and reverse signs of aging. This tool will expand the brands professional-grade offerings, bridging the gap between spa treatments and home care. Join the Celebration From August 1-31, 2025, enjoy exclusive anniversary bundles and discounts on DermRays bestselling devices. Follow @DermRays on social media for giveaways and live demos. About DermRays Since 2011, DermRays has combined dermatological research with accessible technology, offering FDA/CE/UKCA-cleared, non-invasive devices for radiant, youthful skin at home. View original content to download multimedia: SOURCE DermRays
Yahoo
15 hours ago
- Yahoo
Sam Altman's Brain Chip Venture Is Mulling Gene Therapy Approach
(Bloomberg) -- The brain chip company that has drawn interest from Sam Altman and his artificial intelligence business OpenAI is exploring the idea of genetically altering brain cells to make better implants. The US-Canadian Road Safety Gap Is Getting Wider Festivals and Parades Are Canceled Amid US Immigration Anxiety A Photographer's Pipe Dream: Capturing New York's Vast Water System To Head Off Severe Storm Surges, Nova Scotia Invests in 'Living Shorelines' Five Years After Black Lives Matter, Brussels' Colonial Statues Remain The company, which has been referred to as Merge Labs, is looking at an approach involving gene therapy that would modify brain cells, according to people familiar with the plans who weren't authorized to speak publicly on the matter. In addition, an ultrasound device would be implanted in the head that could detect and modulate activity in the modified cells, these people said. It's one of a handful of ideas and technologies the company has been exploring, they said. The venture is still in early stages and could evolve significantly. 'We have not done that deal yet,' Altman told journalists at a dinner Thursday in San Francisco, referring to a question about a brain-computer interface venture. 'I would like us to.' Altman said he wants to be able to think something and have ChatGPT respond to it. Merge Labs is Altman's latest foray into the brain-computer interface field. He is facing off against his longtime rival, Elon Musk, whose company Neuralink is building brain implants with the short-term goal of treating disease and the long-term ambition of improving human abilities. OpenAI declined to comment. Brain-computer interface companies aim to build devices that connect computers to brains and augment peoples' cognition. Implants are currently enabling paralyzed patients to control electronics and helping people communicate who are unable to talk. Technology billionaires and investors are also optimistic that noninvasive devices worn outside of the head could treat mental health conditions. The Financial Times reported this week that Merge is aiming to raise $250 million at an $850 million valuation. Much of that support will come from OpenAI's ventures team, according to the report. Altman is co-founding the company but not personally investing in it, according to the Financial Times. Altman has also invested in Neuralink, Elon Musk's brain implant startup. Neuralink, along with several other companies, is developing chips that communicate with the brain using electrical signals, not ultrasound. For years, researchers have been studying how to genetically change cells to make them respond to ultrasound, a field called sonogenetics. The idea Merge is considering to combine ultrasound with gene therapy could take years, some of the people said. Ultrasound has attracted significant attention recently as a possible brain therapy. Other companies are exploring the idea of using ultrasound transmitters outside the brain to massage brain tissue, with the goal of treating psychiatric conditions. That kind of technology has shown promise in research studies. Coinbase co-founder Fred Ehrsam's company Nudge, which is aiming to build a helmet that beams low-intensity focused ultrasound into the brain, recently raised $100 million. LinkedIn co-founder Reid Hoffman is leading a $12 million funding round in a similar company. --With assistance from Shirin Ghaffary. What Declining Cardboard Box Sales Tell Us About the US Economy Americans Are Getting Priced Out of Homeownership at Record Rates Bessent on Tariffs, Deficits and Embracing Trump's Economic Plan Twitter's Ex-CEO Is Moving Past His Elon Musk Drama and Starting an AI Company Dubai's Housing Boom Is Stoking Fears of Another Crash ©2025 Bloomberg L.P.
WebMD
18 hours ago
- WebMD
Healing in Motion: My Journey With Physical Therapy After Breast Cancer Treatment
There are so many benefits to physical therapy, especially after surgery, trauma, or injury. While I understood this conceptually, I had never personally experienced physical therapy – until I truly needed it. A few months after my breast cancer surgery, I underwent radiation therapy. I hadn't yet considered physical therapy, but I remember the exact moment I realized just how necessary it was. I was reaching for something – I don't recall what – but I couldn't lift my arm high enough to grab it. I tried to move slowly, hoping that would help, but no matter what I did, my arm stopped short. I had just turned 33 and thought to myself, 'This can't be my reality going forward.' At my next appointment, I shared my limited range of motion with my oncologist. She recommended physical therapy – and thus, a new challenge began. I was lucky to find a physical therapist near my home who specialized in oncology. We began with an evaluation and consultation. My second session was tough. So were the many that followed. I remember feeling weak and defeated; the pain brought me to tears. But deep down, I knew the journey would be worth it. Little by little, I began to see progress – not only in my range of motion but in the way my body felt. The persistent pain and tightness that had restricted me started to melt away. With each session, I gained something invaluable: hope, strength, and a deep appreciation for movement. My therapy included targeted massages, scar tissue work, and icing after each visit. I truly believe this hands-on care enhanced my recovery. The scar massage, in particular, helped with both healing and the overall appearance and texture of my skin. One of the things I loved most about my physical therapy plan was its simplicity. Most of the stretches and exercises could be done at home, with little to no equipment. Resistance bands and a foam roller were helpful but not required – unless prescribed by your therapist. What I learned along the way: Your body has already endured so much. Be patient. Be kind. Celebrate how far you've come, even on the tough days. Physical therapy taught me not only how to regain strength, but how to honor my healing. It's important to know: It's never too late to start physical therapy. But the sooner you begin, the sooner you'll start feeling better – physically, emotionally, and mentally. You deserve to treat yourself gently and embrace every small victory.
